Skip to content
Safety ProfileEvidence-Based

Ipamorelin Side Effects

Honest, evidence-based safety analysis for Ipamorelin. Frequency data, severity classification, data limitations, and what we genuinely don't know.

Quick Answer

Ipamorelin has one of the most favorable side-effect profiles among GH secretagogues. Commonly reported effects are mild headache, transient dizziness, and injection site irritation. Unlike GHRP-2 and GHRP-6, ipamorelin does not cause significant cortisol elevation, prolactin spikes, or appetite stimulation. Water retention is less pronounced than with CJC-1295 alone. No serious adverse events have been documented in preclinical studies.

→ Ipamorelin Dosage→ Ipamorelin Benefits→ Full Ipamorelin Profile
Table of Contents

Data Context: What We Actually Know

Important: data limitations

Human side-effect data for ipamorelin derives primarily from anecdotal self-reports and a very limited number of short-term clinical observations. No placebo-controlled human safety studies have been published. Long-term safety is unknown. The information below represents the best available evidence from preclinical research and community reports.

Side Effects by Severity

MildModerateSevere / Serious
Headache (especially early in use)Mild

Frequency: Common — estimated 20–35% of users in first 1–2 weeks

Related to acute GH elevation and vasodilation. Typically diminishes significantly after 1–2 weeks.

Lightheadedness or dizziness shortly after injectionMild

Frequency: Uncommon — ~10–15% anecdotally

Transient, usually resolves within 30 minutes. Related to acute vasodilation. Sitting or lying down after injection reduces occurrence.

Injection site irritation (redness, minor swelling)Mild

Frequency: Common — ~20–30% with subcutaneous injection

Standard subcutaneous injection reaction. Rotate sites. Use proper aseptic technique.

Mild nauseaMild

Frequency: Rare — <5% anecdotally, dose-dependent

Less common than with other GHRPs. Usually at higher doses (300+ mcg). Diminishes with continued use.

Water retentionMild

Frequency: Uncommon — less than with CJC-1295 alone; ~15% anecdotally

GH-mediated sodium and water retention. More common in the first 2–4 weeks.

Potential insulin resistance (long-term, theoretical)Moderate

Frequency: Unknown — no direct evidence from ipamorelin studies

GH elevation causes insulin resistance. Whether the degree of GH elevation from ipamorelin is sufficient for clinically meaningful insulin resistance is unknown. Monitor fasting glucose with extended use.

Contraindications

  • ✕Active cancer or history of hormone-sensitive malignancies (elevated IGF-1 may promote growth)
  • ✕Diabetes or significant insulin resistance (GH elevation may worsen glycemic control)
  • ✕Pregnancy and breastfeeding (no safety data)
  • ✕Active acromegaly or other pituitary disorders

Drug Interactions

No formal pharmacokinetic drug interaction studies have been conducted for most research peptides. The interactions below are theoretical, mechanism-based, or derived from limited case reports.
  • ⚠Insulin and diabetes medications: GH-mediated insulin resistance may require dose adjustment
  • ⚠Glucocorticoids: may attenuate pituitary response to GH secretagogues
  • ⚠Other GH secretagogues (GHRP-2, GHRP-6): additive GH effects — avoid combining unless specifically designed stack
  • ⚠CJC-1295: standard intended combination — synergistic, no known adverse interaction

Frequently Asked Questions

What are ipamorelin's side effects?
Ipamorelin's most commonly reported side effects are mild headache (especially in the first few weeks), occasional lightheadedness after injection, injection site irritation, and mild water retention. Compared to other GHRPs (GHRP-2, GHRP-6), ipamorelin does NOT cause significant cortisol elevation, prolactin spikes, or appetite stimulation. This clean profile is its defining pharmacological advantage.
Does ipamorelin cause cortisol increase?
This is ipamorelin's most important differentiating characteristic: No — at standard doses, ipamorelin does not significantly elevate cortisol or ACTH. This was confirmed in the original pharmacology studies comparing ipamorelin head-to-head against other GHRPs. GHRP-2 and GHRP-6 both cause meaningful cortisol increases; ipamorelin does not. This makes ipamorelin preferable for protocols where stress hormone management is important.
Why do I get headaches from ipamorelin?
The headache is typically related to the acute GH pulse causing vasodilation (expansion of blood vessels). This is transient and normally resolves within 1–2 hours. Headaches are most common in the first 1–2 weeks and diminish as the body adapts to GH elevation. Staying well-hydrated helps. Starting with a lower dose (100 mcg) and titrating up reduces headache occurrence.
Does ipamorelin cause water retention?
Less so than direct GH injection or high-dose CJC-1295 protocols. Some mild water retention is possible in the first few weeks as GH mediates sodium and water retention. This is generally less pronounced with ipamorelin than with synthetic HGH or high-dose CJC-1295 DAC. Reducing carbohydrate intake and adequate hydration help minimize this effect.
Is ipamorelin safe to use?
Ipamorelin has an excellent preclinical safety profile and is considered one of the safest GH secretagogues based on available evidence. No significant organ toxicity or serious adverse events have been documented in animal studies. Human experience is largely anecdotal but generally positive. Long-term human safety data is absent. Standard precautions apply: no use during pregnancy, active cancer, or diabetes without medical supervision.

References

  1. 1
    Ipamorelin, the first selective growth hormone secretagogue(1999)PubMed ↗
  2. 2
    Ipamorelin — a new growth hormone releasing peptide(1998)PubMed ↗
  3. 3
    The selective GH secretagogue ipamorelin activates the hypothalamic GH axis(2000)PubMed ↗

Last updated: 2026-02-26